P47phox transduced autologous CD34+ stem-cell therapy - Cell Genesys/Baxter Healthcare
Alternative Names: Chronic granulomatous disease stem-cell therapy - Cell Genesys/Baxter HealthcareLatest Information Update: 16 Jul 2002
At a glance
- Originator Baxter International; Cell Genesys
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic granulomatous disease
Most Recent Events
- 16 Jul 2002 Discontinued - Phase-I for Chronic granulomatous disease in USA (Infusion)
- 12 Dec 2001 No-Development-Reported for Chronic granulomatous disease in USA (Infusion)
- 08 Apr 1997 New profile